COMMUNIQUÉS West-GlobeNewswire

Evelo Biosciences Reports Fourth Quarter and Full Year 2018 Financial Results and Business Highlights

14/02/2019 - 13:00

-- First Patient Dosed in University of Chicago Phase 2a Trial of EDP1503 in Metastatic Melanoma -- -- Preclinical Studies Have Shown Non-replicating Monoclonal Microbials Maintain Activity: EDP1867 in Development [...]

Axogen, Inc. to Report Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on February 26, 2019

14/02/2019 - 13:00

ALACHUA, Fla., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced [...]

Agios Reports Fourth Quarter and Full Year 2018 Financial Results

14/02/2019 - 13:00

– Strong Launch of TIBSOVO ® Continues with Net Revenue of $9.4M for the Fourth Quarter and $13.8M for Full Year 2018 – – Phase 3 ClarIDHy Trial of TIBSOVO ® in Second Line or Later Cholangiocarcinoma Fully Enrolled [...]

Aravive Expands Executive Team with Promotion of Gail McIntyre, PhD, DABT to Chief Scientific Officer

14/02/2019 - 13:00

HOUSTON, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, announced that the company has promoted Gail McIntyre, PhD, DABT to chief scientific officer. “Aravive [...]

Breathtec Announces Name Change to Algernon Pharmaceuticals

14/02/2019 - 13:00

New corporate identity aligned with the Company's main strategy to be a global leader in the treatment of liver disease (NASH), chronic kidney disease and inflammatory bowel disease. The company's ticker symbol will [...]

Canada House Wellness Group Inc. Accelerates Phenotyping of 62 In-House Genetics

14/02/2019 - 13:00

TORONTO, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Canada House Wellness Group Inc. (“Canada House” or the “Company”) (CSE:CHV) and Abba Medix Corp. (“Abba”), CHV’s wholly owned Licensed Producer has accelerated their [...]

Axovant Announces Formation of Arvelle Therapeutics and Strategic Transition of Legacy Small Molecule Team Into Newly Formed Company

14/02/2019 - 13:00

Transition of small molecule expertise to Arvelle completes transformation of Axovant into a company focused exclusively on gene therapies Axovant will receive a preferred equity stake in Arvelle, which has received [...]

Codexis Announces Nestlé Health Science Exercises Option for Exclusive Global License to CDX-6114 for the Management of Phenylketonuria

14/02/2019 - 13:00

REDWOOD CITY, Calif., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces that Nestlé Health Science has exercised its option to obtain an exclusive license [...]

Amarin to Present at the 8th Annual SVB Leerink Global Healthcare Conference

14/02/2019 - 12:00

BEDMINSTER, N.J., and DUBLIN, Ireland, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve [...]

Terveystalo Plc: Notice of the Annual General Meeting

14/02/2019 - 08:06

Terveystalo Plc Stock Exchange Release 14 February 2019 at 9:05 EET Notice is given to the shareholders of Terveystalo Plc of the Annual General Meeting to be held on Thursday, 4 April 2019 at 3:00 p.m. at Marina [...]

Terveystalo Plc: Terveystalo Group Financial Statements Bulletin 2018

14/02/2019 - 08:01

Terveystalo Plc Stock Exchange Release 14 February 2019 at 9:00 EET Record year, strong platform for growth October-December 2018 in brief Revenue increased by 4.2 percent year-on-year to EUR 197.9 million (189.9) [...]

Ossur Hf : Annual General Meeting 7 March 2019

14/02/2019 - 08:01

Announcement no. 10/2019 14 February 2019 Össur hf. - Annual General Meeting 7 March 2019 Össur hf.'s Annual General Meeting will be held on Thursday 7 March 2019 at 9:00 am (GMT) at the Company's offices at Grjótháls 5 [...]

Motif Bio Receives Complete Response Letter from the FDA

14/02/2019 - 08:00

NEW YORK, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced today that the Company has received a [...]

Addex and Indivior to Accelerate Additional GABAB PAM Compounds for Addiction as Indivior Elects to Stop Development of ADX71441

14/02/2019 - 08:00

Geneva, Switzerland, 14 th February 2019 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, and Indivior PLC (LON: INDV) announced today that they [...]

MDxHealth (R): MDxHealth Signs Partnership with LifeLabs to Make SelectMDx available in Canada

14/02/2019 - 07:01

NEWS RELEASE IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CET, February 14, 2019 - MDxHealth SA (Euronext: MDXH.BR) today announces that it has signed an exclusive distribution agreement with LifeLabs to make SelectMDx ® , [...]

MDxHealth (R) : MDxHealth conclut un partenariat avec LifeLabs pour commercialiser SelectMDx au Canada

14/02/2019 - 07:01

COMMUNIQUÉ DE PRESSE IRVINE, CA, et HERSTAL, BELGIQUE - 07h00 CET, 14 février 2019 - MDxHealth SA (Euronext : MDXH.BR) annonce aujourd'hui qu'elle a signé un accord de distribution exclusive avec LifeLabs pour [...]

Xeris Pharmaceuticals Announces Pricing of Public Offering of Shares of Common Stock

14/02/2019 - 01:26

CHICAGO, Feb. 13, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable [...]

Caladrius Biosciences Reports Top-Line Data for the Phase 2a Sanford Project: T-Rex Trial of CLBS03 for Recent Onset Type 1 Diabetes

13/02/2019 - 23:26

BASKING RIDGE, N.J., Feb. 13, 2019 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company with multiple development [...]

Mesoblast Financial Results Webcast for Half Year, Q2 Ended December 31, 2018

13/02/2019 - 23:06

NEW YORK and MELBOURNE, Australia, Feb. 13, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) will report financial results for the half year and second quarter ended December 31, 2018 in a webcast [...]